2022
Cardiac Complications of Human Babesiosis
Spichler-Moffarah A, Ong E, O’Bryan J, Krause PJ. Cardiac Complications of Human Babesiosis. Clinical Infectious Diseases 2022, 76: e1385-e1391. PMID: 35983604, PMCID: PMC10169432, DOI: 10.1093/cid/ciac525.Peer-Reviewed Original ResearchConceptsYale-New Haven HospitalCardiac complicationsRisk factorsIntensive care unit stayCardiovascular disease risk factorsHuman babesiosisCommon cardiac complicationHigh-grade parasitemiaLife-threatening complicationsDisease risk factorsLonger median lengthQT interval prolongationHigh mortality rateUnit stayComplication groupTick-borne diseaseAdult patientsCardiac outcomesMost patientsThin blood smearsHeart failureInterval prolongationModerate illnessRecord reviewAtrial fibrillation
2021
The Global Emergence of Human Babesiosis
Kumar A, O’Bryan J, Krause PJ. The Global Emergence of Human Babesiosis. Pathogens 2021, 10: 1447. PMID: 34832603, PMCID: PMC8623124, DOI: 10.3390/pathogens10111447.Peer-Reviewed Original ResearchHuman babesiosisPrimary clinical characteristicsEndemic diseaseGlobal health burdenHard-bodied ticksMode of transmissionFulminant casesTick-borne diseaseClinical characteristicsBlood transfusionDisease locationHealth burdenOrgan transplantationEpidemiologic toolIntraerythrocytic protozoaDiseaseBabesiosisInfectionLike agentsGlobal emergenceHuman pathogensUnited StatesBabesiaWide spectrumPredominant species
2019
Persistence of Babesia microti Infection in Humans
Bloch EM, Kumar S, Krause PJ. Persistence of Babesia microti Infection in Humans. Pathogens 2019, 8: 102. PMID: 31319461, PMCID: PMC6789900, DOI: 10.3390/pathogens8030102.Peer-Reviewed Original ResearchTransfusion-transmitted babesiosisBabesia microti infectionBlood donor screeningImmune evasive strategiesPeripheral blood smearFifth of casesHost immune mechanismsNovel therapeutic measuresNovel preventive approachesHIV/AIDSTick-borne diseaseRed blood cellsSevere complicationsAnti-parasitic drugsBlood transfusionImmunocompetent individualsImmunosuppressive drugsDonor screeningMicroti infectionImmune mechanismsBlood donorsHealth burdenImmunoglobulin preparationsNew anti-parasitic drugsTherapeutic measuresHuman babesiosis
Krause PJ. Human babesiosis. International Journal For Parasitology 2019, 49: 165-174. PMID: 30690090, DOI: 10.1016/j.ijpara.2018.11.007.Peer-Reviewed Original ResearchConceptsBurden of infectionSignificant health burdenNon-endemic areasTick-borne diseaseThin blood smearsBlood transfusionExchange transfusionHealth burdenSevere casesBlood smearsHuman babesiosisIntraerythrocytic parasitesTransfusionInfectionBabesiosisBurdenProtective measuresBabesia DNAClindamycinAzithromycinAtovaquoneDiseaseSmearsDiagnosis
2014
Monitoring Human Babesiosis Emergence through Vector Surveillance New England, USA - Volume 20, Number 2—February 2014 - Emerging Infectious Diseases journal - CDC
Diuk-Wasser MA, Liu Y, Steeves TK, Folsom-O'Keefe C, Dardick KR, Lepore T, Bent SJ, Usmani-Brown S, Telford SR, Fish D, Krause PJ. Monitoring Human Babesiosis Emergence through Vector Surveillance New England, USA - Volume 20, Number 2—February 2014 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2014, 20: 225-231. PMID: 24447577, PMCID: PMC3901474, DOI: 10.3201/eid2002.130644.Peer-Reviewed Original ResearchConceptsHuman babesiosisInfectious Diseases journal - CDCProtozoan Babesia microtiDisease-endemic areasTick-borne diseaseBabesiosis-endemic areasSame tick vectorInfection rateInfection ratioTick infection ratesLyme diseaseBabesia microtiHuman casesDiseaseDisease expansionBabesiosisReservoir hostsTick vectorHuman diseasesSurveillanceClose association